“Supervision of Autoimmunity by Foxp3 Regulatory T Cells”

David Hafler, MD
William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology;
Chair, Department of Neurology, Yale School of Medicine
Neurologist-in-Chief, Yale New Haven Hospital

Date: January 22, 2019 at 4pm
Location: The Anlyan Center – TAC N203

Seminar Host: Dr. Stephanie Eisenbarth
Course Director: Dr. Stephanie Eisenbarth and Dr. Carrie Lucas

There is no corporate support for this activity. This activity is not supported by any educational grants.
This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT
The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will understand:
1. The role of FoxP3 regulatory T cells in autoimmune disease
2. Non-functional Tregs secrete IFN gamma
3. CD4 T cells in normal human brain have an inflammatory signature

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
David Hafler: Received consulting fees from Compass Therapeutics, EMD Serono, Novartis Pharmaceuticals, Sanofi Genzyme, and Versant Venture; Served on SAB for Genentech and Proclara Bioscience; Received research funding from Genentech and Bristol-Myers Squibb
Stephanie Eisenbarth: None
Carrie Lucas: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.